COMMUNIQUÉS West-GlobeNewswire

Progenics Pharmaceuticals to Present at the 2018 RBC Capital Markets Global Healthcare Conference
15/02/2018
NEW YORK, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX ), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, [...]
Portola Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on Wednesday, February 28, 2018
15/02/2018
SOUTH SAN FRANCISCO, Calif., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ® (NASDAQ: PTLA ) today announced that it will host a webcast and conference call to discuss the Company’s financial results [...]
Accelerate Diagnostics reports Q4 and Full-Year Financial Results for 2017
15/02/2018
TUCSON, Ariz., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. today announced preliminary full-year 2017 financial results including the quarter ending December 31, 2017. The company reported revenue for [...]
Akcea Announces FDA Advisory Committee Meeting to Review Volanesorsen as a Treatment for Familial Chylomicronemia Syndrome
15/02/2018
CAMBRIDGE, Mass., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA ), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious [...]
Ovid Therapeutics to Present at the RBC Capital Markets 2018 Global Healthcare Conference
15/02/2018
NEW YORK, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID ), a biopharmaceutical company committed to developing medicines for patients with rare neurological disorders, today announced that Yaron [...]
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2017 Financial Results, Provide Corporate Update, Host Conference Call
15/02/2018
MENLO PARK, Calif., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT ) today announced it will report its 2017 financial results and provide a corporate update on February 22, 2018. The [...]
Dova Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Operating and Financial Results
15/02/2018
DURHAM, N.C., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA ), a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for rare diseases where there is [...]
Affimed Announces Closing of Public Offering of Common Stock and Exercise of Underwriters' Option to Purchase Additional Shares
15/02/2018
Heidelberg, Germany, February 15, 2018 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced the closing [...]
Allscripts announces fourth quarter and 2017 full-year results
15/02/2018
Fourth quarter GAAP revenue $517 million, $547 million non-GAAP, representing growth of 22 and 27 percent, respectively, year-over-year Fourth quarter GAAP EPS of $0.03; non-GAAP EPS of $0.18, up 29% Y/Y, the highest [...]
Allscripts to sell OneContent business to Hyland
15/02/2018
CHICAGO, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Allscripts (NASDAQ: MDRX ) has signed a definitive agreement to sell its OneContent business to Hyland Software, Inc., a leading provider of content services solutions to the [...]
Cytokinetics, Inc. Reports Fourth Quarter 2017 Financial Results
15/02/2018
Company Provides 2018 Financial Guidance and Expected Milestones; Reduced Operating Expenses vs. 2017; Over Two Years of Cash Based on Current Burn Rate CK-2127107 Advancing in Four Clinical Trials Under Collaboration [...]
Burgess Source Achieves HITRUST CSF® Certification to Further Mitigate Risk in Third Party Privacy, Security and Compliance
15/02/2018
ALEXANDRIA, Va., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Burgess, an innovator in healthcare payment operations for over 20 years, today announced that Burgess Group's Source Application has earned Certified status for [...]
Inovalon to Participate at 2018 RBC Capital Markets Global Healthcare Conference
15/02/2018
BOWIE, Md., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Inovalon (Nasdaq: INOV ), a leading technology company providing advanced, cloud-based platforms empowering a data-driven transformation from volume-based to value-based [...]
LHC Group Announces Fourth Quarter and Year-End 2017 Earnings Release and Conference Call Dates
15/02/2018
LAFAYETTE, La., Feb. 15, 2018 (GLOBE NEWSWIRE) -- LHC Group, Inc . (NASDAQ: LHCG ) today announced details for the release of its results for the fourth quarter and year ended December 31, 2017. LHC Group plans to issue [...]
FDA Accepts New Drug Application and Grants Priority Review for Ivosidenib in Relapsed or Refractory AML with an IDH1 Mutation
15/02/2018
– PDUFA date set for August 21, 2018 – CAMBRIDGE, Mass., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO ), a leader in the field of cellular metabolism to treat cancer and rare genetic [...]
Diaxonhit : Distribution exclusive de la plateforme de biologie moléculaire VERIGENE®
15/02/2018
Distribution exclusive de la plateforme de biologie moléculaire VERIGENE® Diaxonhit devient, par l'intermédiaire de sa filiale eurobio-ingen, le distributeur exclusif de la gamme de biologie moléculaire VERIGENE® de la [...]
GUERBET : 2017 revenue at constant exchange rates: €812.4 million; +4.7%
15/02/2018
Villepinte, February 15, 2018 - Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is reporting revenue of €807.1 million at December 31, 2017, up by 4.0% at current [...]
GUERBET : Chiffre d'affaires 2017 à taux de change constant : 812,4 M€ ; +4,7%
15/02/2018
Villepinte, le 15 février 2018 - Guerbet (FR0000032526 GBT), spécialiste mondial des produits de contraste et solutions pour l'imagerie médicale, publie un chiffre d'affaires de 807,1 M€ au 31 décembre 2017, en [...]
Catalyst Biosciences Announces Closing of Public Offering of Common Stock
15/02/2018
SOUTH SAN FRANCISCO, Calif., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO ), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology [...]

Pages